Investors on the quest for market-beating returns often employ the strategy of stock picking. Making informed choices in stocks can greatly amplify your wealth.
As of close of business last night, Sarepta Therapeutics Inc’s stock clocked out at $54.43, down -7.13% from its previous closing price of $58.61. In other words, the price has decreased by -$7.13 from its previous closing price. On the day, 4.58 million shares were traded. SRPT stock price reached its highest trading level at $59.45 during the session, while it also had its lowest trading level at $54.26.
Ratios:
To gain a deeper understanding of SRPT’s stock, we examine its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 3.18 and its Current Ratio is at 4.20. In the meantime, Its Debt-to-Equity ratio is 0.88 whereas as Long-Term Debt/Eq ratio is at 0.87.
On March 31, 2025, RBC Capital Mkts Downgraded its rating to Sector Perform which previously was Outperform and also lowered its target price recommendation from $161 to $87.
On February 11, 2025, Deutsche Bank started tracking the stock assigning a Hold rating and target price of $136.Deutsche Bank initiated its Hold rating on February 11, 2025, with a $136 target price.
Insider Transactions:
Investing in insider trades can also provide an investor with insight into how management views future stock prices. A recent insider transaction in this stock occurred on Mar 12 ’25 when Nicaise Claude sold 2,491 shares for $99.64 per share. The transaction valued at 248,203 led to the insider holds 27,812 shares of the business.
Nicaise Claude bought 2,491 shares of SRPT for $248,226 on Mar 12 ’25. On Dec 12 ’24, another insider, Wigzell Hans Lennart Rudolf, who serves as the Director of the company, sold 10,500 shares for $124.84 each. As a result, the insider received 1,310,820 and left with 22,840 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, SRPT now has a Market Capitalization of 5281457152 and an Enterprise Value of 5269533696. As of this moment, Sarepta’s Price-to-Earnings (P/E) ratio for their current fiscal year is 22.84, and their Forward P/E ratio for the next fiscal year is 4.24. The expected Price-to-Earnings-to-Growth (PEG) calculation for the next 5 years is 0.26. For the stock, the TTM Price-to-Sale (P/S) ratio is 2.78 while its Price-to-Book (P/B) ratio in mrq is 3.45. Its current Enterprise Value per Revenue stands at 2.771 whereas that against EBITDA is 20.6.
Stock Price History:
The Beta on a monthly basis for SRPT is 0.85, which has changed by -0.5693488 over the last 52 weeks, in comparison to a change of -0.024663687 over the same period for the S&P500. Over the past 52 weeks, SRPT has reached a high of $173.25, while it has fallen to a 52-week low of $57.14. The 50-Day Moving Average of the stock is -43.96%, while the 200-Day Moving Average is calculated to be -55.46%.
Shares Statistics:
It appears that SRPT traded 1.51M shares on average per day over the past three months and 2724140 shares per day over the past ten days. A total of 96.90M shares are outstanding, with a floating share count of 91.14M. Insiders hold about 6.07% of the company’s shares, while institutions hold 91.27% stake in the company. Shares short for SRPT as of 1741910400 were 4853902 with a Short Ratio of 3.21, compared to 1739491200 on 4919665. Therefore, it implies a Short% of Shares Outstanding of 4853902 and a Short% of Float of 5.2199997.
Dividends & Splits
Against a Trailing Annual Dividend Yield of 0.0
